Evexomostat

DB19140InvestigationalSmall molecule

Evexomostat is under investigation in clinical trial NCT05570253 (A Study of SDX-7320 in Combination With Eribulin for People With Breast Cancer).

Mechanism
Curator reviewed
Also known as
METAP2 inhibitor SDX-7320 · Poly((n-(2-hydroxypropyl)methacrylamide)-co-(methacryloyl-gly-phe-leu-gly amide with o-((trans-4-aminocyclohexyl)carbamoyl)fumagillol)) (~0.91:0.09 x)
Code names
SDX-7320

Resolves to

Compound
UNIIZ7116W3IFACAS2416263-67-5
Targets
P50579METAP2

What you can answer from here — as of July 09, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action
Listed above
3Clinical trialsPhase, status and sponsor resolved per trial
Sign in
3+ReferencesStructured and connected to the statements they support
Sign in

Which drugs share a target with Evexomostat, and which of those have an active Phase 3 trial?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In